The SELECT Trial: Semaglutide 2.4 mg and Cardiovascular Outcomes in Obesity

Why SELECT mattered before the results were in

For decades, the regulatory and payer case for obesity pharmacotherapy rested almost entirely on weight reduction and its effects on metabolic parameters: blood pressure, glycemia, lipids. Direct evidence that reducing body weight with a drug could lower the rate of heart attacks and strokes in people without diabetes was absent. Orlistat, liraglutide 3.0 mg, and naltrexone-bupropion either lacked a dedicated cardiovascular outcomes trial or had inconclusive or interrupted CVOT data.

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity, NCT03574597) was specifically designed to fill this gap. By enrolling only participants without diabetes, it isolated the cardiovascular question from any glycemic confound: if semaglutide reduced MACE in this population, the benefit would have to be attributed to weight loss, direct vascular effects of the drug, or both, rather than to glucose lowering.

Trial design

SELECT enrolled 17,604 adults aged 45 or older with a BMI of 27 or greater and established cardiovascular disease (prior myocardial infarction, prior stroke, or symptomatic peripheral arterial disease), and without type 2 diabetes (HbA1c below 6.5% and fasting plasma glucose below 126 mg/dL at baseline). Participants were randomized 1:1 to once-weekly subcutaneous semaglutide 2.4 mg (dose-escalated over 16 weeks from 0.25 mg) or matching placebo, added to standard-of-care cardiovascular treatment including statins, antihypertensives, and antiplatelet agents.^[1]

The primary endpoint was time to first occurrence of the three-component MACE composite: cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. The trial was event-driven, with a target of 1,225 primary endpoint events and a planned median follow-up of approximately five years; actual median follow-up was approximately 40 months.

Primary results

The primary composite MACE endpoint occurred in 6.5% of semaglutide participants versus 8.0% of placebo participants, a hazard ratio of 0.80 (95% confidence interval 0.72 to 0.90, p < 0.001), representing a 20% relative risk reduction.^[1]All three components of the composite showed consistent directional effects:

• Cardiovascular death: HR 0.85 (95% CI 0.71 to 1.01); numerically favoring semaglutide, not statistically significant individually.
• Non-fatal myocardial infarction: HR 0.72 (95% CI 0.61 to 0.85); statistically significant.
• Non-fatal stroke: HR 0.93 (95% CI 0.74 to 1.15); directionally favoring semaglutide but not individually significant.

Pre-specified analyses showed that the cardiovascular benefit was consistent across subgroups defined by sex, age, region, baseline BMI, and baseline HbA1c category, though the absolute risk reduction was greatest in the highest-risk participants.

Weight loss and the cardiovascular benefit question

Participants in the semaglutide arm lost approximately 9.4% of body weight at 104 weeks, compared with approximately 0.9% in the placebo group.^[2]The weight separation was maintained throughout follow-up, making it plausible that weight loss contributed to the MACE reduction. However, SELECT was not designed to disentangle weight-mediated from weight-independent mechanisms.

Semaglutide also improved blood pressure, lipids, C-reactive protein, and glycemic indices (preventing progression to diabetes in at-risk participants) relative to placebo. Whether any of these intermediate changes explain the CV benefit independently of the weight effect is a question that requires mediation analysis and mechanistic investigation beyond the scope of the trial's primary endpoints.

Several secondary analyses published after the primary paper examined whether the MACE benefit was larger in participants who lost more weight, but the results were consistent across weight-loss quartiles, suggesting that weight change does not fully explain the cardiovascular effect and that direct vascular biology of GLP-1 receptor agonism may play a role.

Regulatory and clinical impact

In March 2024, the FDA updated the Wegovy label to include a cardiovascular risk reduction indication, citing the SELECT data. This made Wegovy the first and, as of the last review date, only weight-management drug with an FDA-approved claim for reduction of serious cardiovascular events. The EMA similarly updated the Wegovy label for the EU market.

The SELECT result reshaped the reimbursement debate in the United States. The cardiovascular indication created a pathway for Medicare Part D coverage under a preventive cardiology framing, something that had been explicitly excluded for obesity pharmacotherapy under prior CMS interpretation. In early 2024, CMS announced a proposed rule to allow Medicare coverage of semaglutide 2.4 mg specifically for the cardiovascular indication in eligible beneficiaries, though final implementation timelines remained subject to rulemaking at the time of the last review date.

For cardiologists and preventive medicine practitioners, SELECT provided the evidence to begin thinking of semaglutide 2.4 mg as a cardiovascular therapy that also reduces weight, rather than a weight therapy with unproven cardiovascular effects. The framing shift has practical consequences for which specialty is likely to initiate and monitor the treatment in high-risk patients.

Open questions after SELECT

• Does the cardiovascular benefit extend to patients with lower CVD risk (primary prevention)? SELECT enrolled only those with established CVD; outcomes in those with risk factors but no prior event are unknown.
• Is there a class effect? The SURMOUNT-MMO trial (tirzepatide in obesity) and the FLOW trial (semaglutide in chronic kidney disease, which includes CV outcomes) will add evidence from related agents and indications. FLOW (NCT03819153) reported a renal benefit with semaglutide 1.0 mg in 2024.
• How durable is the CV benefit if treatment is stopped, given the weight-regain observed in STEP-4?
• What is the mechanism of the non-fatal MI reduction, which was the most statistically statistically strong individual MACE component? Direct anti-inflammatory, lipid, or plaque-stability effects are candidate mechanisms not resolvable from the SELECT dataset alone.